| Target Price | $25.50 |
| Price | $10.68 |
| Potential |
138.76%
register free of charge
|
| Number of Estimates | 7 |
|
7 Analysts have issued a price target KemPharm, Inc. 2026 .
The average KemPharm, Inc. target price is $25.50.
This is
138.76%
register free of charge
$30.45
185.11%
register free of charge
$18.18
70.22%
register free of charge
|
|
| A rating was issued by 14 analysts: 13 Analysts recommend KemPharm, Inc. to buy, 1 to hold and 0 to sell. | |
| Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
|
Analyst Estimates: Analysts believe that the KemPharm, Inc. stock has an average upside potential 2026 of
138.76%
register free of charge
|
| Dec '24 |
2025 Estimates |
|
|---|---|---|
| Revenue Million $ | 23.61 | 103.05 |
| 14.02% | 336.47% | |
| EBITDA Margin | -341.42% | -72.45% |
| 92.91% | 78.78% | |
| Net Margin | -446.89% | 65.56% |
| 166.48% | 114.67% |
10 Analysts have issued a sales forecast KemPharm, Inc. 2025 . The average KemPharm, Inc. sales estimate is
This results in the following potential growth metrics:
3 Analysts have issued an KemPharm, Inc. EBITDA forecast 2025. The average KemPharm, Inc. EBITDA estimate is
This results in the following potential growth metrics and future EBITDA Margins:
10 KemPharm, Inc. Analysts have issued a net profit forecast 2025. The average KemPharm, Inc. net profit estimate is
This results in the following potential growth metrics and future Net Margins:
| Dec '24 |
2025 Estimates |
|
|---|---|---|
| Earnings Per Share $ | -2.28 | 1.23 |
| 75.38% | 153.95% | |
| P/E | 8.71 | |
| EV/Sales | 4.70 |
10 Analysts have issued a KemPharm, Inc. forecast for earnings per share. The average KemPharm, Inc. EPS is
This results in the following potential growth metrics and future valuations:
| Analyst | Rating | Action | Date |
|---|---|---|---|
| JMP Securities |
Locked
➜
Locked
|
Locked | Aug 13 2025 |
| Cantor Fitzgerald |
Locked
➜
Locked
|
Locked | Jul 10 2025 |
| HC Wainwright & Co. |
Locked
➜
Locked
|
Locked | Jul 02 2025 |
| Cantor Fitzgerald |
Locked
➜
Locked
|
Locked | May 14 2025 |
| Guggenheim |
Locked
➜
Locked
|
Locked | Mar 13 2025 |
| HC Wainwright & Co. |
Locked
➜
Locked
|
Locked | Mar 13 2025 |
| Canaccord Genuity |
Locked
➜
Locked
|
Locked | Mar 13 2025 |
| Analyst Rating | Date |
|---|---|
|
Locked
JMP Securities:
Locked
➜
Locked
|
Aug 13 2025 |
|
Locked
Cantor Fitzgerald:
Locked
➜
Locked
|
Jul 10 2025 |
|
Locked
HC Wainwright & Co.:
Locked
➜
Locked
|
Jul 02 2025 |
|
Locked
Cantor Fitzgerald:
Locked
➜
Locked
|
May 14 2025 |
|
Locked
Guggenheim:
Locked
➜
Locked
|
Mar 13 2025 |
|
Locked
HC Wainwright & Co.:
Locked
➜
Locked
|
Mar 13 2025 |
|
Locked
Canaccord Genuity:
Locked
➜
Locked
|
Mar 13 2025 |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.


